RAMAT GAN, Israel--(BUSINESS WIRE)--IOPtima, the developer of an innovative laser based surgical device for reducing internal eye pressure for the treatment of glaucoma, successfully completed and analyzed the results of its first 6 month follow-up period of human clinical trials. IOPtima’s novel, laser-based technology enables eye surgeons to perform a simple and safe surgery and reduce internal eye pressure without penetrating the eye membrane. Elevated internal eye pressure, or intra-ocular pressure (“IOP”), is a key cause / risk factor of glaucoma, which in many cases causes the deterioration in the visual field and ultimately can lead to blindness without proper treatment to reduce and control IOP. The procedure, utilizing IOPtima technology, was performed with local anesthesia on an out-patient basis, and was demonstrated in these trials to be both safe and efficacious as a means to reduce IOP.
